证券日报网讯 8月29日晚间，同仁堂发布公告称，公司第十届董事会第十三次会议审议通过了《2025年 半年度报告全文及其摘要》等多项议案。 （文章来源：证券日报） ...

Core Insights - The company reported a revenue of 9.769 billion yuan for the first half of 2025, reflecting a year-on-year growth of 0.06% [1] - The net profit attributable to shareholders decreased by 7.39% to 945 million yuan, while the net profit excluding non-recurring items fell by 5.03% [1] Business Overview - The company's main business involves the production and sales of traditional Chinese medicine (TCM), with a complete industry chain that includes TCM material planting, processing, research and development, logistics distribution, and wholesale and retail [1] - The company produces over 400 varieties of TCM, with a diverse range of product forms covering various medical categories such as internal medicine, surgery, gynecology, and pediatrics [1] - Notable products include An Gong Niu Huang Wan, Tong Ren Niu Huang Qing Xin Wan, Tong Ren Da Huo Luo Wan, Liu Wei Di Huang Wan, and Jin Kui Shen Qi Wan, which are well-known both domestically and internationally [1]

格隆汇8月29日｜ 同仁堂 (600085.SH)公告称，2025年上半年实现营业收入97.69亿元，同比增长 0.06%，归属于上市公司股东的净利润为9.45亿元，同比下降7.39%。 ...

北京同仁堂股份有限公司 2025 年度"提质增效重回报"行动方案半年度评估报告 双轮驱动，构建品牌文化和经济效益的良性互动机制。围绕重点品种与区域市场， 精准施策，拓展半空白市场空间，推进品种良性发展与高效运营，持续强化渠道 支撑与品牌影响力。推进渠道、终端管控工作，加强流通秩序管控，统一规划部 署，线上线下协同布局，深挖电商渠道和医疗市场潜力，确保营销工作统筹推进。 受行业周期调整和外部市场压力影响，公司阶段性增长节奏有所放缓。截止 2025 年 6 月 30 日，公司合并报表总资产 319.47 亿元，归属于上市公司股东的所 有者权益 134.31 亿元，上半年合并报表实现营业收入 97.69 亿元，实现归属于上 市公司股东的净利润 9.45 亿元，经营活动产生的现金流量净额 19.53 亿元。面对 政策趋严、行业竞争加剧等复杂环境，公司着力提升核心业务协同能力，整体经 营运行平稳有序，核心业务稳中提质，展现了一定的抗压能力、运营韧性和发展 潜能。 下半年，公司将继续保持战略发展定力，集中力量做好主责主业，紧扣全年 "提质增效"目标，加强工业端与商业端精准协调，研判市场需求，合理规划产 品结构和生产节奏。 ...

证券代码：600085 证券简称：同仁堂 公告编号：2025-028 北京同仁堂股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2025 年 8 月 30 日披露了《北京同仁堂股份有限公司 2025 年半年度 报告》，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果及财务 状况，公司计划于 2025 年 9 月 5 日（星期五）上午 9:30-10:30 通过上海证券报·中 国证券网（http://roadshow.cnstock.com/）召开"同仁堂 2025 年半年度业绩说明 会"，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络文字互动方式召开，公司将针对 2025 年半年度的 经营成果及财务指标的具体情况等与投资者进行互动交流和沟通，在信息披露允 许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 召开时间：2025 年 9 月 5 日（星期五） 上午 9:30-10:30 召开 ...

第十届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 北京同仁堂股份有限公司（以下简称公司）第十届董事会第十三次会议于 2025 年 8 月 28 日在公司会议室以现场结合通讯会议方式召开。本次会议通知已 提前送达全体董事，与会各位董事均已知悉与本次会议所议事项的相关必要信息。 本次董事会会议应出席董事 9 人，实际出席 9 人。公司部分高级管理人员列席了 本次会议。会议由董事长张朝华女士主持，会议的召开和表决程序符合《中华人 民共和国公司法》及《北京同仁堂股份有限公司章程》的有关规定。 二、会议审议情况 证券代码：600085 证券简称：同仁堂 公告编号：2025-027 北京同仁堂股份有限公司 （二） 审议通过了《2025 年度"提质增效重回报"行动方案半年度评估报 告》 公司积极响应上海证券交易所开展"提质增效重回报"专项行动公开倡议， 于 2025 年 4 月 4 日发布《2025 年度"提质增效重回报"行动方案》（以下简称《行 动方案》）。2025 年上半年，公司以提升经 ...

北京同仁堂股份有限公司 2025 年半年度报告 公司代码：600085 公司简称：同仁堂 北京同仁堂股份有限公司 2025 年半年度报告 1 / 172 北京同仁堂股份有限公司 2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张朝华、主管会计工作负责人潘宝侠及会计机构负责人（会计主管人员）王燕 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 □适用 √不适用 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报告中详细 描述了存在的风险事项，请查阅本报告第三节"管理层讨论 ...

Core Viewpoint - The company is actively transforming the traditional Chinese medicine industry through scientific and standardized practices, showcasing its capabilities in national strategic research and innovation [1][3]. Group 1: Research and Development Initiatives - The company has been approved as the leading unit for a national pharmacopoeia standard research project, focusing on the "Guiding Principles for the Determination of Biological Activity of Traditional Chinese Medicine" [1]. - The project aims to establish a "component-activity-efficacy" evaluation system to enhance quality control in traditional Chinese medicine, addressing common industry challenges [1][3]. - The innovative drug "Qi Shen Granules," a completely new type of traditional Chinese medicine, has successfully completed Phase II clinical production and is intended for chronic heart failure treatment [3]. Group 2: Quality Control and Standards - The company has implemented three new group standards for traditional Chinese medicine traceability in collaboration with the China Traditional Chinese Medicine Association [3]. - The company has achieved CNAS accreditation for its testing centers, indicating compliance with international standards and enhancing its competitive edge in both domestic and international markets [4][7]. - The focus on "zero defect quality management" is reinforced by high-quality inspection levels and ongoing improvements in laboratory standardization [4]. Group 3: Future Directions - The company plans to continue driving high-quality development through a dual-engine strategy of "quality" and "innovation," increasing resource investment to enhance its core competitiveness [7].

Core Insights - Tongrentang Technology is leveraging data assets as a core strategic resource and value growth engine, enhancing operational efficiency and quality control through a deep integration of data across the entire value chain from cultivation to terminal sales [1][8] - The company has established a comprehensive traceability system for over 40 traditional Chinese medicine varieties, ensuring quality control and enhancing brand value through transparent data management [2][4] - A national sales data direct connection system has been implemented, allowing real-time aggregation of inventory and sales data from over 600 distributors and 4,000 retail terminals, enabling agile decision-making and market responsiveness [2][4] Data-Driven Decision Making - The sales data system allows for rapid response to market changes, exemplified by a 20% increase in sales of a specific product due to local weather conditions, leading to timely adjustments in inventory and distribution [4][7] - The integration of a production visualization system and SCADA technology has transformed production processes into data-driven operations, significantly improving efficiency and reducing labor costs [7][8] Quality Control and Production Efficiency - The production management dashboard provides real-time monitoring of key production metrics, enhancing the ability to identify and address bottlenecks quickly [5][7] - Post-implementation of the data-driven production system, the company reported a 40% increase in packaging line capacity and a 25% reduction in labor costs, while maintaining high product quality standards [7][8] Future Outlook - Tongrentang Technology plans to continue investing in digital operations, focusing on the integration of AI, predictive maintenance, and IoT technologies to further enhance efficiency and create sustainable long-term value [8]

Core Viewpoint - The development of high-quality talent is essential for the growth of the traditional Chinese medicine (TCM) industry, with a focus on cultivating high-skilled professionals to support the sector's innovation and quality improvement [2][4]. Group 1: Talent Development and Competitions - The "Tongrentang Cup" skills competition was held to enhance talent cultivation and selection, promoting the inheritance of TCM culture [3][5]. - A total of 724 employees participated in the competition, showcasing a strong commitment to mastering skills and contributing to the company's culture [3]. - Outstanding participants will have the opportunity to become representatives of intangible cultural heritage (ICH) within the company by 2025 [4]. Group 2: Intangible Cultural Heritage and Innovation - Tongrentang Group currently has 15 ICH projects, including 4 national-level projects, and has recently recognized new representatives of ICH [4][5]. - The company actively engages in various events to promote its ICH projects, enhancing their visibility and relevance in modern contexts [5]. - Future plans include recognizing at least 300 foundational ICH inheritors and 150 representative inheritors within the next five years, ensuring the continuity and vitality of traditional skills [5].